ACE-I on CKD progression in CKD without DM Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data Jafar et al.141 MEDLINE References used to check and supplement reference list of ERT systematic review Topic 6. Anti-hypertensive agents in kidney-transplant recipients Anti-hypertensives for kidney-transplant recipients: Systematic review and meta-analysis of randomized controlled trials Cross et al.301 Cochrane Renal Group Specialized Register Cochrane CENTRAL MEDLINE Embase Up to July 1, 2008 References used to check and supplement reference list of ERT systematic review ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; ERT, evidence review team; RAS, renin angiotensin system. Table 8 | Literature yield Studies included in summary tables Intervention Abstracts identified Articles retrieved Studies with data extracted DKD Non-DKD Transplant General population studies in summary tables Summary tables Agents DKD, diabetic kidney disease. methods for guideline development July 2002, the search for the current KDIGO Guideline included publications since January 2002. Search strategies were developed by the ERT with input from the Work Group. The text words or medical subject headings (MeSH) that were included are provided in the Supplementary Appendix 1 online. Non-human studies and those focusing on dialysis, pregnancy, neonates, malignant hypertension, acute kidney injury, or drug pharmacology were excluded. The MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched by the ERT to capture all RCTs on the use of BP-lowering agents in CKD. The first search was conducted in November 2009 and was subsequently updated in April and August of 2010; the final update was done in January 2011. 